Table III.

Univariate Analysis of Patient Characteristics by 25-hydroxyvitamin D category. Data presented as median (25^th – 75^th percentile).

	n	25-hydroxyvitamin D deficient (serum <15 ng/ml) n=9	25-hydroxyvitamin D insufficient (serum 15-30 ng/ml) n=41	25-hydroxyvitamin D sufficient (serum > 30 ng/ml) n=28	p-value*
Age (years) at study visit	78	17.6 (17.3 – 20.3)	15.2 (11.8 – 16.4)	14.2 (10.3 – 16.5)	0.01
Gender (% male)	78	44% (4)	46% (19)	64% (18)	0.30
Race (% Caucasian)	78	56% (5)	73% (30)	89% (25)	0.08
Years from Diagnosis	78	10.0 (6.0 – 12.0)	10.0 (6.0 – 12.0)	10.0 (7.0 – 12.0)	0.98
CRT	78	33% (3)	20% (8)	18% (5)	0.59
TBI	78	33% (3)	34% (14)	32% (9)	0.99
Diagnosis of growth hormone deficiency	27	11% (1)	22% (9)	18% (5)	0.27
Hypothyroidism	27	11% (1)	7% (3)	18% (5)	0.37
HOMA	77	1.9 (1.0 – 3.7)	1.6 (1.0 – 2.8)	1.3 (0.8 – 2.5)	0.46
Height z-score	70	-0.44 (-0.64 – -0.02)	-0.32 (-0.96 – 0.90)	0.02 (-0.48 – 0.75)	0.59
Weight z-score	70	1.13 (0.74 – 1.43)	0.86 (-0.29 – 1.58)	0.51 (-0.13 – 0.93)	0.35
BMI z-score	74	0.82 (0.43 – 1.68)	0.82 (0.16 – 1.77)	0.66 (0.12 – 1.24)	0.52
UV 30**	78	2.4 (1.3 – 4.3)	4.5 (1.5 – 6.7)	5.4 (3.8 – 6.8)	0.08
Vitamin D intake/ day (IU) ***	76	148 (121 – 182)	292 (148 – 370)	274 (175 – 427)	0.07
% meeting RDA for vitamin D intake	76	0% (0)	20% (8)	29% (8)	0.19
Calcium intake/ day (mg) **	76	835 (610 – 951)	1148 (719 – 1688)	1098 (827 – 1695)	0.11
% meeting RDA for calcium intake	76	11% (1)	39% (16)	46% (13)	0.16
% receiving vitamin D supplements	76	11% (1)	17.1% (7)	39.3% (11)	0.08

^*For continuous variables Kruskal-Wallis test, for categorical variables the Pearson chi-square test;

^**UV30: a measurement of the average amount of UV light in the patient's geographic location during the 30 days prior to the serum vitamin D evaluation;

^***Reported dietary intake, not including supplement use